Free Trial
NASDAQ:UTHR

United Therapeutics (UTHR) Stock Price, News & Analysis

United Therapeutics logo
$319.86 +6.87 (+2.19%)
Closing price 04:00 PM Eastern
Extended Trading
$319.92 +0.06 (+0.02%)
As of 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About United Therapeutics Stock (NASDAQ:UTHR)

Key Stats

Today's Range
$313.18
$320.67
50-Day Range
$304.42
$380.78
52-Week Range
$221.53
$417.82
Volume
376,139 shs
Average Volume
446,565 shs
Market Capitalization
$14.37 billion
P/E Ratio
14.05
Dividend Yield
N/A
Price Target
$388.25
Consensus Rating
Moderate Buy

Company Overview

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Remove Ads

United Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
88th Percentile Overall Score

UTHR MarketRank™: 

United Therapeutics scored higher than 88% of companies evaluated by MarketBeat, and ranked 108th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    United Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 9 buy ratings, 2 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    United Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about United Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for United Therapeutics are expected to grow by 12.30% in the coming year, from $24.48 to $27.49 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of United Therapeutics is 14.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.53.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of United Therapeutics is 14.05, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.70.

  • Price to Earnings Growth Ratio

    United Therapeutics has a PEG Ratio of 0.97. PEG Ratios around 1 indicate that a company is correctly valued.

  • Price to Book Value per Share Ratio

    United Therapeutics has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about United Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    5.58% of the float of United Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    United Therapeutics has a short interest ratio ("days to cover") of 6.1.
  • Change versus previous month

    Short interest in United Therapeutics has recently increased by 18.84%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    United Therapeutics does not currently pay a dividend.

  • Dividend Growth

    United Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.58% of the float of United Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    United Therapeutics has a short interest ratio ("days to cover") of 6.1.
  • Change versus previous month

    Short interest in United Therapeutics has recently increased by 18.84%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    United Therapeutics has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for United Therapeutics this week, compared to 12 articles on an average week.
  • Search Interest

    Only 5 people have searched for UTHR on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,995,021.00 in company stock.

  • Percentage Held by Insiders

    11.90% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about United Therapeutics' insider trading history.
Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

UTHR Stock News Headlines

Trump Makes Major Crypto Announcement
Trump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now.
Zacks Research Issues Pessimistic Outlook for UTHR Earnings
United Therapeutics price target lowered to $314 from $328 at BofA
See More Headlines

UTHR Stock Analysis - Frequently Asked Questions

United Therapeutics' stock was trading at $352.84 at the beginning of the year. Since then, UTHR stock has decreased by 9.3% and is now trading at $319.86.
View the best growth stocks for 2025 here
.

United Therapeutics Co. (NASDAQ:UTHR) issued its earnings results on Wednesday, February, 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. The biotechnology company had revenue of $735.90 million for the quarter, compared to analysts' expectations of $734.74 million. United Therapeutics had a trailing twelve-month return on equity of 19.22% and a net margin of 40.31%.

United Therapeutics' top institutional shareholders include Wealthfront Advisers LLC (41.02%), Vanguard Group Inc. (9.95%), Avoro Capital Advisors LLC (6.18%) and Wellington Management Group LLP (5.49%). Insiders that own company stock include Paul A Mahon, James Edgemond, Judy D Olian, Nilda Mesa, Louis W Sullivan, Christopher Causey, Michael Benkowitz, Raymond Dwek, Martine A Rothblatt and Christopher Patusky.
View institutional ownership trends
.

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that United Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

Last Earnings
2/26/2025
Today
3/24/2025
Next Earnings (Estimated)
4/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:UTHR
Employees
980
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$388.25
High Stock Price Target
$600.00
Low Stock Price Target
$280.00
Potential Upside/Downside
+21.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
12 Analysts

Profitability

Trailing P/E Ratio
14.05
Forward P/E Ratio
13.07
P/E Growth
0.97
Net Income
$984.80 million
Pretax Margin
52.17%

Debt

Sales & Book Value

Annual Sales
$2.88 billion
Cash Flow
$19.23 per share
Price / Cash Flow
16.63
Book Value
$127.35 per share
Price / Book
2.51

Miscellaneous

Free Float
39,332,000
Market Cap
$14.37 billion
Optionable
Optionable
Beta
0.64

Social Links

Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:UTHR) was last updated on 3/24/2025 by MarketBeat.com Staff
From Our Partners